Organogenesis Achieves Primary Endpoint In Phase 3 Clinical Trial Of ReNu for Knee Osteoarthritis

5/2/24 7:44:04 AM ET

$ORGO

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ORGO alert in real time by email

Statistically significant (p=0.0177) reduction in knee pain at six months

Statistically significant (p<0.0001) maintenance of function at six months
Transformational opportunity for Organogenesis to enter large and growing pain management market with innovative therapy
- Will address critical unmet medical need for all knee OA patients, including the most severe, if approved

Get the next $ORGO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ORGO

Date	Price Target	Rating	Analyst
6/28/2024	$5.00	Buy	Lake Street
2/7/2024	$5.00	Overweight	Cantor Fitzgerald
6/15/2023	$5.00	Equal-Weight	Morgan Stanley
5/24/2023	$10.00	Neutral → Buy	BTIG Research
11/10/2022		Buy → Neutral	BTIG Research
8/10/2022		Outperform → Perform	Oppenheimer
11/10/2021	$26.00 → $20.00	Outperform	SVB Leerink
8/10/2021	$24.00 → $25.00	Outperform	Credit Suisse

More analyst ratings

$ORGO
Press Releases

Fastest customizable press release news feed in the world

Organogenesis Expands Manufacturing Capacity to Support Future Growth
CANTON, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, announced plans to expand manufacturing capacity with a long-term lease for a 122,000-square foot state-of-the-art biomanufacturing facility located at 100 Technology Way in Smithfield, Rhode Island. "We are pleased to join the Rhode Island life sciences community as we expand our New England manufacturing capacity to support future growth," said Gary S. Gillheeney, Sr., President, Chief Executive Officer, a
11/22/24 4:05:00 PM ET
$ORGO
Biotechnology: Pharmaceutical Preparations
Health Care
Organogenesis Commends Final LCDs
CANTON, Mass., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, commends today's decision by the U.S. Centers for Medicare & Medicaid Services (CMS) on local coverage determination (LCD) based on peer-reviewed and evidence-based data of clinical efficacy. The LCD covers skin substitute grafts/cellular and tissue-based products (CTP) for the treatment of diabetic foot ulcers (DFU) and venous leg ulcers (VLU) in the Medicare population and is now set to become effective on
11/15/24 9:25:44 AM ET
$ORGO
Biotechnology: Pharmaceutical Preparations
Health Care
Organogenesis Holdings Inc. Reports Third Quarter 2024 Financial Results
CANTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Results Summary: Net revenue of $115.2 million for the third quarter of 2024, an increase of $6.6 million compared to net revenue of $108.5 million for the third quarter of 2023. Net revenue for the third quarter of 2024 consists of: Net revenue from Advanced Wound Care products of $108.0 million, an
11/12/24 4:05:00 PM ET
$ORGO
Biotechnology: Pharmaceutical Preparations
Health Care

$ORGO
Market Insights

Live Market Insights

Lake Street Initiates Coverage On Organogenesis Hldgs with Buy Rating, Announces Price Target of $5
Lake Street analyst Brooks O'Neil initiates coverage on Organogenesis Hldgs (NASDAQ:ORGO) with a Buy rating and announces Price Target of $5.
6/28/24 8:14:05 AM ET
$ORGO
Biotechnology: Pharmaceutical Preparations
Health Care
Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Diodes Incorporated (NASDAQ:DIOD) fell sharply during Friday's session after the company reported worse-than-expected quarterly financial results. Diodes posted adjusted earnings of 28 cents per share, missing market estimates of 31 cents per share. The company's quarterly sales came in at $301.97 million missing expectations of $305.01 million, according to data from Benzinga Pro. Diodes shares dipped 9.8% to $68.99 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Novavax, Inc. (NASDAQ:NVAX) shares jumped 139% to $10.73 after the company and Sanofi announced a co-exclusive licensing agreement to commercialize a COVID-19 vaccine and d
5/10/24 12:44:44 PM ET
$ACIC
$ADMA
$AEHL
$AFRM
Property-Casualty Insurers
Finance
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Novavax (NASDAQ:NVAX) stock increased by 110.7% to $9.42 during Friday's regular session. The market value of their outstanding shares is at $1.3 billion. The company's, Q1 earnings came out today. Portage Biotech (NASDAQ:PRTG) stock increased by 57.97% to $0.41. The market value of their outstanding shares is at $8.1 million. ITeos Therapeutics (NASDAQ:ITOS) stock rose 46.92% to $17.91. The company's market cap stands at $644.1 million. As per the press release, Q1 earnings came out today. Sensus Healthcare (NASDAQ:SRTS) stock moved upwards by 37.87% to $5.25. The company's market cap stands at $86.1 million. As per the press release, Q1 earnings came out yesterday. Cardio Diag
5/10/24 12:31:07 PM ET
$BFRI
$CDIO
$GRTS
$IOVA
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: Biological Products (No Diagnostic Substances)

$ORGO
Financials

Live finance-specific insights

Organogenesis Holdings Inc. Reports Third Quarter 2024 Financial Results
CANTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Results Summary: Net revenue of $115.2 million for the third quarter of 2024, an increase of $6.6 million compared to net revenue of $108.5 million for the third quarter of 2023. Net revenue for the third quarter of 2024 consists of: Net revenue from Advanced Wound Care products of $108.0 million, an
11/12/24 4:05:00 PM ET
$ORGO
Biotechnology: Pharmaceutical Preparations
Health Care
Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2024 Financial Results on November 12, 2024
CANTON, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that third quarter of fiscal year 2024 financial results will be reported after the market closes on Tuesday, November 12th. Management will host a conference call at 5:00 p.m. Eastern Time on November 12th to discuss the results of the quarter and provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access the
10/16/24 7:30:00 AM ET
$ORGO
Biotechnology: Pharmaceutical Preparations
Health Care
Organogenesis Holdings Inc. Reports Second Quarter 2024 Financial Results
CANTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Results Summary: Net revenue of $130.2 million for the second quarter of 2024, an increase of $12.9 million compared to net revenue of $117.3 million for the second quarter of 2023. Net revenue for the second quarter of 2024 consists of: Net revenue from Advanced Wound Care products of $123.2 million, an
8/8/24 4:05:00 PM ET
$ORGO
Biotechnology: Pharmaceutical Preparations
Health Care

Organogenesis Expands Manufacturing Capacity to Support Future Growth
CANTON, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, announced plans to expand manufacturing capacity with a long-term lease for a 122,000-square foot state-of-the-art biomanufacturing facility located at 100 Technology Way in Smithfield, Rhode Island. "We are pleased to join the Rhode Island life sciences community as we expand our New England manufacturing capacity to support future growth," said Gary S. Gillheeney, Sr., President, Chief Executive Officer, a
11/22/24 4:05:00 PM ET
$ORGO
Biotechnology: Pharmaceutical Preparations
Health Care
Organogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred Stock
CANTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that it has entered into a Subscription Agreement with affiliates of Avista Healthcare Partners ("Investors") for the sale of its Series A Convertible Preferred Stock ("Preferred Stock") in a private placement for gross proceeds of $130 million to the Company, prior to deducting placement agent commissions, fees and other offering expenses. The Company intends to use the net proceeds from the
11/12/24 4:01:00 PM ET
$ORGO
Biotechnology: Pharmaceutical Preparations
Health Care
Bionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation and Next Stage of Strategic Growth
Alan Fisher appointed Chair of the Board of DirectorsTim Cunningham joins as Chief Financial Officer ADELAIDE, Australia and CAMBRIDGE, Mass., July 03, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX, ASX: BNO))) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced key leadership updates to drive its ongoing transformation to a U.S.-focused company, streamline its allocation of capital, and support its next stage of strategic growth. Alan Fisher, currently a non-executive me
7/3/23 6:00:00 AM ET
$BNOX
$ORGO
Biotechnology: Pharmaceutical Preparations
Health Care

Organogenesis Achieves Primary Endpoint In Phase 3 Clinical Trial Of ReNu for Knee Osteoarthritis

Chat with this insight

Recent Analyst Ratings for $ORGO

$ORGO Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13D filed by Organogenesis Holdings Inc.

Amendment: SEC Form SC 13D/A filed by Organogenesis Holdings Inc.

Amendment: SEC Form SC 13G/A filed by Organogenesis Holdings Inc.

$ORGO Press Releases

Fastest customizable press release news feed in the world

Organogenesis Expands Manufacturing Capacity to Support Future Growth

Organogenesis Commends Final LCDs

Organogenesis Holdings Inc. Reports Third Quarter 2024 Financial Results

$ORGO Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Lake Street initiated coverage on Organogenesis with a new price target

Cantor Fitzgerald initiated coverage on Organogenesis with a new price target

Morgan Stanley initiated coverage on Organogenesis with a new price target

$ORGO Market Insights

Live Market Insights

Lake Street Initiates Coverage On Organogenesis Hldgs with Buy Rating, Announces Price Target of $5

Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session

12 Health Care Stocks Moving In Friday's Intraday Session

$ORGO Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$ORGO SEC Filings

New insider Avista Capital Managing Member Vi, Llc claimed ownership of 3,734,021 shares (SEC Form 3)

New insider Lustig Garrett claimed ownership of 27,339 shares (SEC Form 3)

Large owner Erani Albert disposed of $2,575,156 worth of shares (815,000 units at $3.16) and returned $20,875,288 worth of shares to the company (6,606,731 units at $3.16), decreasing direct ownership by 13% to 51,585,403 units (SEC Form 4)

Organogenesis Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

SEC Form 10-Q filed by Organogenesis Holdings Inc.

$ORGO Financials

Live finance-specific insights

Organogenesis Holdings Inc. Reports Third Quarter 2024 Financial Results

Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2024 Financial Results on November 12, 2024

Organogenesis Holdings Inc. Reports Second Quarter 2024 Financial Results

$ORGO Leadership Updates

Live Leadership Updates

Organogenesis Expands Manufacturing Capacity to Support Future Growth

Organogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred Stock

Bionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation and Next Stage of Strategic Growth

Recent Analyst Ratings for
$ORGO

$ORGO
Large Ownership Changes

$ORGO
Press Releases

$ORGO
Analyst Ratings

$ORGO
Market Insights

$ORGO
Insider Trading

$ORGO
SEC Filings

$ORGO
Financials

$ORGO
Leadership Updates